Literature DB >> 16715252

Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.

Tuomo Puustjärvi1, Markku Teräsvirta, Pila Nurmenniemi, Jukka Lokkila, Hannu Uusitalo.   

Abstract

BACKGROUND: The aim of the study was to evaluate the vitreous penetration of two commercially available ophthalmic fluoroquinolones: ofloxacin and levofloxacin.
METHODS: This prospective, double-blind, randomized clinical trial comprised 16 patients scheduled for vitrectomy surgery of one eye for macular hole or macular pucker. The patients were randomly assigned to receive topical ofloxacin 0.3% (n=9) or levofloxacin 0.5% (n=7) the day before, one drop at noon, 4 p.m., 8 p.m. and midnight. The next morning, patients were given their assigned masked antibiotic every 5 min for four doses starting 1 h before surgery. The vitreous humour samples, at least 0.3 ml each, were collected 1 h after the administration of the last dose, at the beginning of the pars plana vitrectomy with infusion disconnected. Samples were assayed for ofloxacin and levofloxacin concentrations by a method using high-performance liquid chromatography (HPLC) coupled with single mass spectrometry with electrospray ionization
RESULTS: Equal topical administration of levofloxacin yielded 2.5 times higher vitreal concentration than ofloxacin. The mean vitreous concentrations of ofloxacin and levofloxacin were 5.30+/-3.04 (SD) ng/ml and 13.09+/-5.24 ng/ml, respectively (P=0.002).
CONCLUSIONS: Equal dosing with topical administration of levofloxacin 0.5% and ofloxacin 0.3% allows better penetration into the vitreous for levofloxacin, but the levels of mean concentrations of each drug did not exceed the MIC(90) or MIC(50) for most ocular pathogenic bacteria in terms of conventional endophthalmitis therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16715252     DOI: 10.1007/s00417-006-0360-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  25 in total

1.  Penetration of ofloxacin in human aqueous and vitreous humors following oral and topical administration.

Authors:  O Cekic; C Batman; U Yasar; N E Basci; A Bozkurt; S O Kayaalp
Journal:  Retina       Date:  1998       Impact factor: 4.256

2.  Preventing, diagnosing, and treating endophthalmitis.

Authors:  S Masket
Journal:  J Cataract Refract Surg       Date:  1998-06       Impact factor: 3.351

3.  Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis.

Authors:  N V Prajna; C George; S Selvaraj; K L Lu; P J McDonnell; M Srinivasan
Journal:  Cornea       Date:  2001-03       Impact factor: 2.651

4.  A retrospective study of endophtalmitis rates comparing quinolone antibiotics.

Authors:  Michael K Jensen; Richard G Fiscella; Alan S Crandall; Majid Moshirfar; Barbara Mooney; Trevin Wallin; Randall J Olson
Journal:  Am J Ophthalmol       Date:  2005-01       Impact factor: 5.258

5.  Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.

Authors:  Rookaya Mather; Lisa M Karenchak; Eric G Romanowski; Regis P Kowalski
Journal:  Am J Ophthalmol       Date:  2002-04       Impact factor: 5.258

6.  Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.

Authors:  Seenu M Hariprasad; Kevin J Blinder; Gaurav K Shah; Rajendra S Apte; Brett Rosenblatt; Nancy M Holekamp; Matthew A Thomas; William F Mieler; Jingduan Chi; Randall A Prince
Journal:  Arch Ophthalmol       Date:  2005-01

7.  Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients.

Authors:  Steven J Lichtenstein; Mike Rinehart
Journal:  J AAPOS       Date:  2003-10       Impact factor: 1.220

8.  Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group.

Authors:  T P O'Brien; M G Maguire; N E Fink; E Alfonso; P McDonnell
Journal:  Arch Ophthalmol       Date:  1995-10

9.  [In vitro topically applied fluoroquinolone penetration into the anterior chamber].

Authors:  M Fukuda; K Sasaki
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1995-05

10.  Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.

Authors:  J P Diamond; L White; J P Leeming; H Bing Hoh; D L Easty
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

View more
  3 in total

1.  Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.

Authors:  Abdhish R Bhavsar; Joseph M Googe; Cynthia R Stockdale; Neil M Bressler; Alexander J Brucker; Michael J Elman; Adam R Glassman
Journal:  Arch Ophthalmol       Date:  2009-12

2.  Pseudomonas aeruginosa choroidal abscess in a patient with bronchiectasis.

Authors:  Kenneth K W Li; Emily W H Tang; Jimmy S M Lai; David Wong
Journal:  Int Ophthalmol       Date:  2007-08-09       Impact factor: 2.031

3.  Aqueous humour concentrations after topical apPlication of combinEd levofloxacin-dexamethasone eye dRops and of its single components: a randoMised, assEssor-blinded, parallel-group study in patients undergoing cataract surgery: the iPERME study.

Authors:  Michele Figus; Chiara Posarelli; Dario Romano; Marco Nardi; Luca Rossetti
Journal:  Eur J Clin Pharmacol       Date:  2020-04-13       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.